Literature DB >> 24955784

Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis.

B Freeman1, D Brauneis1, D C Seldin1, K Quillen1, J M Sloan1, A S Renteria1, A C Shelton1, T Teschner1, K T Finn1, V Sanchorawala1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24955784     DOI： 10.1038/bmt.2014.132

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  7 in total

1.  Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Authors:  Maria Teresa Cibeira; Vaishali Sanchorawala; David C Seldin; Karen Quillen; John L Berk; Laura M Dember; Adam Segal; Frederick Ruberg; Hans Meier-Ewert; Nancy T Andrea; J Mark Sloan; Kathleen T Finn; Gheorghe Doros; Joan Blade; Martha Skinner
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

2.  High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center.

Authors:  Stephanie B Tsai; David C Seldin; Karen Quillen; John L Berk; Frederick L Ruberg; Hans Meier-Ewert; J Mark Sloan; Gheorghe Doros; Kathleen T Finn; Martha Skinner; Vaishali Sanchorawala
Journal:  Blood       Date:  2012-11-22       Impact factor: 22.113

3.  Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue.

Authors:  B Meisenberg; R Gollard; T Brehm; R McMillan; W Miller
Journal:  Support Care Cancer       Date:  1996-09       Impact factor: 3.603

4.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

5.  Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies.

Authors:  Francesc Fernández-Avilés; Enric Carreras; Alvaro Urbano-Ispizua; Montserrat Rovira; Carmen Martínez; Anna Gaya; Miquel Granell; Laia Ramiro; Cristina Gallego; Adela Hernando; Susana Segura; Lourdes García; Manel González; Montserrat Valverde; Emili Montserrat
Journal:  J Clin Oncol       Date:  2006-09-25       Impact factor: 44.544

6.  High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Authors:  Martha Skinner; Vaishali Sanchorawala; David C Seldin; Laura M Dember; Rodney H Falk; John L Berk; Jennifer J Anderson; Carl O'Hara; Kathleen T Finn; Caryn A Libbey; Janice Wiesman; Karen Quillen; Niall Swan; Daniel G Wright
Journal:  Ann Intern Med       Date:  2004-01-20       Impact factor: 25.391

7.  The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer.

Authors:  W P Peters; M Ross; J J Vredenburgh; A Hussein; P Rubin; K Dukelow; C Cavanaugh; R Beauvais; S Kasprzak
Journal:  Semin Oncol       Date:  1994-08       Impact factor: 4.929
  7 in total
  2 in total

1.  Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma.

Authors:  T M Graff; A K Singavi; W Schmidt; D Eastwood; W R Drobyski; M Horowitz; J Palmer; M Pasquini; D J Rizzo; W Saber; P Hari; T S Fenske
Journal:  Bone Marrow Transplant       Date:  2015-04-13       Impact factor: 5.483

2.  Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis.

Authors:  S Y Lee; R S Meehan; D C Seldin; J M Sloan; K Quillen; A Shelton; D Brauneis; V Sanchorawala
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.